Systemic fungal infections: A pharmacist/researcher perspective

Abbygail C. Spencer, Katelyn R. Brubaker, Sylvie Garneau-Tsodikova

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Systemic fungal infections are increasing in prevalence, especially in immunocompromised patients and post-surgical patients. The rise in systemic fungal infections has resulted in increased utilization of antifungal agents which, in turn, has contributed to escalating resistance rates as seen by the increasing number of fungal pathogens added to the Centers for Disease Control and Prevention Antimicrobial Resistance Threats Report in 2019. Unfortunately, there are few novel antifungal agents coming to market to combat these ever-increasing resistance rates. In this review, we cover the current climate of antifungal agents and explore agents coming through the pipeline and potentially to market. We also discuss the indicated uses for empiric and targeted antifungal therapies as well as the need to include antifungal agents as a part of antimicrobial stewardship programs that focus heavily on antibacterial agents.

Original languageEnglish
Article number100293
JournalFungal Biology Reviews
StatePublished - Jun 2023

Bibliographical note

Publisher Copyright:
© 2022 British Mycological Society


  • Antifungal agent
  • Mechanism of action
  • Stewardship
  • Systemic antifungal coverage
  • Systemic fungal infections

ASJC Scopus subject areas

  • Microbiology


Dive into the research topics of 'Systemic fungal infections: A pharmacist/researcher perspective'. Together they form a unique fingerprint.

Cite this